Company’s recent performance sets path for future milestones, commercialization
Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.
Genprex has initiated the first phase of branding its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.
Genprex today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Genprex reported that its collaborators from The University of Texas MD Anderson Cancer Center presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019.
Genprex today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.
Genprex today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.
Genprex announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.